Skip to Primary Navigation

Skip to main content

Assertio Therapeutics dinged $3.6m over fentanyl false claims

Female doctor with nasal spray
Photo: nensuria/Getty Images

Alexander Barzacanos

1 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The settlement is the latest in a string of False Claims Act enforcement actions against pharmaceutical companies.

Assertio Therapeutics, formerly known as Depomed, will pay $3.6m to settle charges that it caused false claims to be submitted to Medicare and TRICARE when it targeted its advertising at pain specialists who were prescribing high volumes of products similar to its product Lazanda, a nasal spray that contains fentanyl.

, , , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience